RU2017111300A - Центральные т-клетки памяти для адоптивной т-клеточной терапии - Google Patents
Центральные т-клетки памяти для адоптивной т-клеточной терапии Download PDFInfo
- Publication number
- RU2017111300A RU2017111300A RU2017111300A RU2017111300A RU2017111300A RU 2017111300 A RU2017111300 A RU 2017111300A RU 2017111300 A RU2017111300 A RU 2017111300A RU 2017111300 A RU2017111300 A RU 2017111300A RU 2017111300 A RU2017111300 A RU 2017111300A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- human
- population
- central memory
- cell population
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 19
- 238000002659 cell therapy Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 25
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 14
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 10
- 102100033467 L-selectin Human genes 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (20)
1. Популяция человеческих Т-клеток, трансдуцированных вектором, экспрессирующим химерный антигенный рецептор, где по меньшей мере 50% трансдуцированных человеческих Т-клеток представляют собой центральные Т-клетки памяти.
2. Популяция человеческих Т-клеток по п. 1, в которой по меньшей мере 10% трансдуцированных центральных Т-клеток памяти являются CD4+.
3. Популяция человеческих Т-клеток по п. 1, в которой по меньшей мере 10% трансдуцированных центральных Т-клеток памяти являются CD8+.
4. Популяция человеческих Т-клеток по п. 1, в которой по меньшей мере 15% центральных Т-клеток памяти являются CD4+, и по меньшей мере 15% являются CD8+.
5. Популяция человеческих Т-клеток по п. 1, в которой по меньшей мере 50% трансдуцированных человеческих Т-клеток являются CD4+/CD8+/CD62L+.
6. Популяция человеческих Т-клеток, трансдуцированных вектором, экспрессирующим химерный антигенный рецептор, в которой по меньшей мере 50% трансдуцированных человеческих Т-клеток являются CD45R0+, CD62L+ и CD45Ra-, по меньшей мере 10% клеток являются CD4+, и по меньшей мере 10% клеток являются CD4+.
7. Популяция человеческих Т-клеток по п. 6, в которой по меньшей мере 10% клеток, которые являются CD45R0+, CD62L+ и CD45Ra-, также являются CD4+, и по меньшей мере 10% клеток, которые являются CD45R0+, CD62L+ и CD45Ra-, также являются CD8+.
8. Популяция человеческих Т-клеток по п. 6, в которой по меньшей мере 15% клеток, которые являются CD45R0+, CD62L+ и CD45Ra-, также являются CD4+, и по меньшей мере 15% клеток, которые являются CD45R0+, CD62L+ и CD45Ra-, также являются CD4+.
9. Способ лечения рака, включающий введение пациенту, нуждающемуся в этом, фармацевтической композиции, содержащей человеческие Т-клетки по любому из пп. 1-8.
10. Способ по п. 9, в котором популяция человеческих Т-клеток является аутологической по отношению к пациенту.
11. Способ по п. 9, в котором популяция человеческих Т-клеток является аллогенной по отношению к пациенту.
12. Способ получения популяции центральных Т-клеток памяти, включающий: получение популяции Т-клеток от субъекта-человека; обеднение данной популяции Т-клеток клетками, которые экспрессируют CD25, клетками, которые экспрессируют CD14, и клетками, которые экспрессируют CD45+, с получением популяции обедненных Т-клеток; обогащение популяции обедненных Т-клеток клетками, экспрессирующими CD62L, получая, посредством этого, популяцию центральных Т-клеток памяти, где данный способ не включает стадию обеднения популяции клеток клетками, экспрессирующими CD4, и не включает стадию обеднения популяции клеток клетками, экспрессирующими CD8+.
13. Способ по п. 12, в котором по меньшей мере 50% клеток в популяции центральных Т-клеток памяти являются CD45R0+, CD62L+ и CD45Ra-, по меньшей мере 10% клеток являются CD4+, и по меньшей мере 10% клеток являются CD4+.
14. Способ по п. 12, в котором по меньшей мере 50% клеток в популяции центральных Т-клеток памяти являются CD45R0+, CD62L+ и CD45Ra-, по меньшей мере 15% клеток являются CD4+, и по меньшей мере 15% клеток являются CD4+.
15. Способ по п. 12, в котором по меньшей мере 50% клеток в популяции центральных Т-клеток памяти являются CD45R0+, CD62L+ и CD45Ra-, по меньшей мере 20% клеток являются CD4+, и по меньшей мере 20% клеток являются CD4+.
16. Способ по п. 12, дополнительно включающий стимулирование популяции центральных Т-клеток памяти.
17. Способ по п. 16, включающий приведение в контакт популяции центральных Т-клеток памяти с CD3 и/или CD28.
18. Способ по п. 16, дополнительно включающий трансдуцирование клеток вектором, экспрессирующим рекомбинантный белок, для создания популяции генетически модифицированных центральных Т-клеток памяти.
19. Способ по п. 18, дополнительно включающий размножение популяции генетически модифицированных центральных Т-клеток памяти.
20. Способ по п. 19, в котором стадия размножения популяции генетически модифицированных центральных Т-клеток памяти включает подвергание клеток воздействию одного или обоих IL-2 и IL-15.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053068P | 2014-09-19 | 2014-09-19 | |
| US62/053,068 | 2014-09-19 | ||
| PCT/US2015/051280 WO2016044853A1 (en) | 2014-09-19 | 2015-09-21 | Central memory t cells for adoptive t cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017111300A true RU2017111300A (ru) | 2018-10-19 |
| RU2017111300A3 RU2017111300A3 (ru) | 2019-09-04 |
| RU2763523C2 RU2763523C2 (ru) | 2021-12-30 |
Family
ID=55533940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111298A RU2749922C2 (ru) | 2014-09-19 | 2015-09-18 | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 |
| RU2017111300A RU2763523C2 (ru) | 2014-09-19 | 2015-09-21 | Центральные т-клетки памяти для адоптивной т-клеточной терапии |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017111298A RU2749922C2 (ru) | 2014-09-19 | 2015-09-18 | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9914909B2 (ru) |
| EP (4) | EP3587446A1 (ru) |
| JP (7) | JP6657195B2 (ru) |
| KR (3) | KR102683584B1 (ru) |
| CN (4) | CN113789336B (ru) |
| AU (4) | AU2015317351B2 (ru) |
| BR (3) | BR122024000360A2 (ru) |
| CA (2) | CA2961654A1 (ru) |
| DK (1) | DK3200591T3 (ru) |
| ES (2) | ES2738705T3 (ru) |
| IL (6) | IL308324A (ru) |
| MX (4) | MX387135B (ru) |
| RU (2) | RU2749922C2 (ru) |
| WO (2) | WO2016044811A1 (ru) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9738696B2 (en) | 2012-08-09 | 2017-08-22 | The Board Of Trustees Of The Leland Stanford Junior University | Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities |
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| CN113307880B (zh) | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| IL308324A (en) | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
| EA202090931A3 (ru) | 2015-05-18 | 2020-10-30 | Тср2 Терапьютикс Инк. | Композиции и способы перепрограммирования tcr с помощью гибридных белков |
| US12115189B2 (en) | 2015-07-21 | 2024-10-15 | City Of Hope | T cells for expression of chimeric antigen receptors and other receptors |
| RU2724738C2 (ru) * | 2015-08-05 | 2020-06-25 | СеллабМЕД ИНК. | Химерный антигенный рецептор и т-клетки, в которых экспрессируется химерный антигенный рецептор |
| IL261941B2 (en) | 2016-04-01 | 2023-11-01 | Kite Pharma Inc | Chimeric antigen and T cell receptors and methods of use |
| US20190183931A1 (en) * | 2016-04-01 | 2019-06-20 | Amgen Inc. | Chimeric receptors to flt3 and methods of use thereof |
| SI3436030T1 (sl) | 2016-04-01 | 2023-01-31 | Kite Pharma, Inc. | Himerni receptorji in načini njihove uporabe |
| TWI761831B (zh) * | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| US12144850B2 (en) | 2016-04-08 | 2024-11-19 | Purdue Research Foundation | Methods and compositions for car T cell therapy |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| CA3026778A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| CA3025667A1 (en) * | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法 |
| CN110177558B (zh) * | 2016-09-16 | 2025-02-28 | 贝勒医学院 | 用于病毒特异性t细胞的活化和扩增的平台 |
| CN112280796A (zh) | 2016-10-07 | 2021-01-29 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| WO2018132427A1 (en) | 2017-01-10 | 2018-07-19 | The General Hospital Corporation | Targeted t cells with cytotoxicity toward immunosuppressive cells |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CN108395481B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定 |
| US12083148B2 (en) * | 2017-02-22 | 2024-09-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | IL13Ra2-binding chimeric antigen receptors |
| US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
| EP3604344A4 (en) * | 2017-03-27 | 2021-01-06 | Noile-Immune Biotech, Inc. | CHEMICAL ANTIGENIC RECEPTOR |
| WO2018191748A1 (en) | 2017-04-14 | 2018-10-18 | The General Hospital Corporation | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| EP3612210A4 (en) | 2017-04-19 | 2021-01-27 | Board Of Regents, The University Of Texas System | MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| JP7391831B2 (ja) * | 2017-08-11 | 2023-12-05 | シティ・オブ・ホープ | Ｃａｒ ｔ細胞標的を発現する腫瘍溶解性ウイルス、及びその使用 |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| AU2018362014A1 (en) * | 2017-11-03 | 2020-05-28 | Sorrento Therapeutics, Inc. | CD38-directed chimeric antigen receptor constructs |
| WO2019094498A1 (en) * | 2017-11-07 | 2019-05-16 | City Of Hope | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| CA3089051A1 (en) | 2018-01-22 | 2019-07-25 | Endocyte, Inc. | Methods of use for car t cells |
| EP3743445A1 (en) * | 2018-01-26 | 2020-12-02 | City of Hope | Chimeric antigen receptors and methods for reducing off target toxicity |
| EP3749695A4 (en) * | 2018-02-06 | 2021-12-29 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| WO2019157533A1 (en) * | 2018-02-12 | 2019-08-15 | The General Hospital Corporation | Chimeric antigen receptors targeting the tumor microenvironment |
| CN111918661A (zh) | 2018-02-21 | 2020-11-10 | 得克萨斯大学体系董事会 | 用于活化和扩增自然杀伤细胞的方法及其用途 |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| EA202091984A1 (ru) * | 2018-03-14 | 2021-02-18 | Сиэтл Чилдрен'С Хоспитал (Дба Сиэтл Чилдрен'С Ресёрч Инститьют) | Направленная дзетакинами т-клеточная иммунотерапия, нацеленная на рецептор il-13 альфа 2 |
| CA3093810A1 (en) * | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
| AU2019249215A1 (en) | 2018-04-06 | 2020-10-22 | The Regents Of The University Of California | Methods of treating EGFRvIII expressing glioblastomas |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| KR20210013691A (ko) * | 2018-05-21 | 2021-02-05 | 바이오셉터 (유케이) 리미티드 | 수정된 링커 도메인을 갖는 키메라 항원 수용체 및 그 용도 |
| CA3102097A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| CN113260369B (zh) * | 2018-08-10 | 2024-08-23 | 优特力克斯有限公司 | 癌抗原特异性细胞毒性t细胞 |
| SG11202104287RA (en) * | 2018-11-06 | 2021-05-28 | Univ Washington | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same |
| WO2020191336A1 (en) | 2019-03-21 | 2020-09-24 | Yamaguchi, Yukiko | Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl |
| US20220145252A1 (en) | 2019-03-29 | 2022-05-12 | City Of Hope | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors |
| JP2022533247A (ja) * | 2019-05-24 | 2022-07-21 | シティ・オブ・ホープ | Ｃｃｒ４陽性悪性腫瘍治療用ｃｃｒ４標的化キメラ抗原受容体修飾ｔ細胞 |
| WO2021004400A1 (zh) * | 2019-07-06 | 2021-01-14 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| CN112204135A (zh) * | 2019-07-06 | 2021-01-08 | 苏州克睿基因生物科技有限公司 | 一种表达cd3抗体受体复合物的免疫细胞及其用途 |
| KR20220038397A (ko) * | 2019-07-24 | 2022-03-28 | 리제너론 파아마슈티컬스, 인크. | Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도 |
| EP3769816A1 (en) * | 2019-07-25 | 2021-01-27 | Ospedale Pediatrico Bambino Gesù | Car-cd123 vector and uses thereof |
| WO2021138454A1 (en) | 2019-12-30 | 2021-07-08 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
| WO2021154543A2 (en) | 2020-01-31 | 2021-08-05 | City Of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Rα2 POSITIVE MALIGNANCIES |
| WO2021183755A1 (en) * | 2020-03-11 | 2021-09-16 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| EP4118106A1 (en) * | 2020-03-12 | 2023-01-18 | City of Hope | TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES |
| EP4143300A1 (en) | 2020-04-28 | 2023-03-08 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3184784A1 (en) * | 2020-05-27 | 2021-12-02 | The Medical College Of Wisconsin, Inc. | Improved lentiviral vector transfer plasmid and methods of use |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| MX2023001771A (es) * | 2020-08-11 | 2023-04-25 | Yeda Res & Dev | Celulas car-t de veto. |
| IL301233A (en) * | 2020-09-10 | 2023-05-01 | Mustang Bio Inc | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
| US20240009239A1 (en) * | 2020-11-04 | 2024-01-11 | Fred Hutchinson Cancer Center | Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy |
| WO2022109498A1 (en) | 2020-11-23 | 2022-05-27 | City Of Hope | Engineered t cells for expression of chimeric anitgen receptors |
| WO2022120334A1 (en) | 2020-12-03 | 2022-06-09 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN118146395A (zh) * | 2021-02-08 | 2024-06-07 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| WO2022198027A1 (en) * | 2021-03-18 | 2022-09-22 | The Wistar Institute Of Anatomy And Biology | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Rα2 AND METHODS OF USE IN CANCER THERAPEUTICS |
| CN117242090A (zh) | 2021-03-30 | 2023-12-15 | 希望之城公司 | CAR T细胞疗法和IFNγ |
| US20230190799A1 (en) * | 2021-07-21 | 2023-06-22 | City Of Hope | Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy |
| CN113621077B (zh) * | 2021-09-02 | 2023-01-31 | 山东大学 | 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞 |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| WO2023130462A1 (zh) * | 2022-01-10 | 2023-07-13 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的嵌合抗原受体及其用途 |
| CN115960257B (zh) * | 2022-09-29 | 2023-10-27 | 卡瑞济(北京)生命科技有限公司 | 靶向IL13Rα2的经优化的嵌合抗原受体及其用途 |
| EP4588939A1 (en) | 2024-01-16 | 2025-07-23 | Universitat de Barcelona | Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0517895B1 (en) | 1990-12-14 | 1996-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| RU2167676C2 (ru) * | 1995-02-24 | 2001-05-27 | Дзе Дженерал Хоспитал Корпорейшн | Перенаправление клеточного иммунитета посредством химерных рецепторов |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| ATE292473T1 (de) | 1998-07-30 | 2005-04-15 | Us Gov Health & Human Serv | Thymosin beta 4 stimuliert wundheilung |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| EP1263785A2 (en) * | 1999-11-11 | 2002-12-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mutated il-13 molecules and their uses |
| US7560280B2 (en) | 2000-11-03 | 2009-07-14 | Kourion Therapeutics Gmbh | Human cord blood derived unrestricted somatic stem cells (USSC) |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US11278594B2 (en) * | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2002256390B2 (en) | 2001-04-30 | 2007-08-30 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| ATE373904T1 (de) | 2003-07-24 | 2007-10-15 | Matsushita Electric Industrial Co Ltd | Verfahren, kodierer und kommunikationsvorrichtung zur kodierung von parallel verketteten daten |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7754441B2 (en) * | 2003-11-17 | 2010-07-13 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
| DE102004043271A1 (de) * | 2004-09-07 | 2006-03-09 | Linde Ag | Verfahren zur Synthese von Zirkoniumcarboxylaten |
| US20060269973A1 (en) * | 2004-11-24 | 2006-11-30 | Cassian Yee | Methods of using IL-21 for adoptive immunotherapy and identification of tumor antigens |
| CN101346463B (zh) * | 2005-12-21 | 2012-06-13 | 江苏太瑞生诺生物医药科技有限公司 | 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法 |
| US20080293070A1 (en) | 2005-12-21 | 2008-11-27 | Rafick-Pierre Sekaly | Markers for Memory T Cells and Uses Thereof |
| PL2126054T3 (pl) | 2007-01-31 | 2017-01-31 | Yeda Research And Development Company Limited | Przekierowane, genetycznie modyfikowane regulatorowe komórki T i ich zastosowanie w hamowaniu choroby autoimmunologicznej i zapalnej |
| CN101842387B (zh) * | 2007-09-26 | 2014-05-07 | Ucb医药有限公司 | 双特异性抗体融合物 |
| ES2553421T3 (es) * | 2008-08-26 | 2015-12-09 | City Of Hope | Método y composiciones para el funcionamiento potenciado del efector antitumoral de células T |
| US20130011401A1 (en) * | 2009-12-22 | 2013-01-10 | Novartis Ag | Soluble proteins for use as therapeutics |
| GB2481983A (en) * | 2010-07-12 | 2012-01-18 | Hart Fenton & Co Ltd | A ship including a gas tank room |
| US20130164272A1 (en) | 2010-08-18 | 2013-06-27 | Udai S. Kammula | Methods of identifying central memory t cells and obtaining antigen-specific t cell populations |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG193591A1 (en) * | 2011-03-23 | 2013-10-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| BR112013024574B1 (pt) * | 2011-03-29 | 2022-08-09 | Roche Glycart Ag | Anticorpo e uso do anticorpo |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| KR102264290B1 (ko) * | 2012-08-20 | 2021-06-10 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법을 위한 방법 및 조성물 |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| IL308324A (en) | 2014-09-19 | 2024-01-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
-
2015
- 2015-09-18 IL IL308324A patent/IL308324A/en unknown
- 2015-09-18 CA CA2961654A patent/CA2961654A1/en active Pending
- 2015-09-18 JP JP2017515139A patent/JP6657195B2/ja active Active
- 2015-09-18 RU RU2017111298A patent/RU2749922C2/ru active
- 2015-09-18 BR BR122024000360-0A patent/BR122024000360A2/pt not_active Application Discontinuation
- 2015-09-18 ES ES15775539T patent/ES2738705T3/es active Active
- 2015-09-18 KR KR1020177010183A patent/KR102683584B1/ko active Active
- 2015-09-18 EP EP19175730.1A patent/EP3587446A1/en not_active Withdrawn
- 2015-09-18 EP EP15775539.8A patent/EP3194433B1/en active Active
- 2015-09-18 BR BR112017005631-3A patent/BR112017005631A2/pt not_active IP Right Cessation
- 2015-09-18 IL IL292650A patent/IL292650B2/en unknown
- 2015-09-18 CN CN202110969587.7A patent/CN113789336B/zh active Active
- 2015-09-18 AU AU2015317351A patent/AU2015317351B2/en active Active
- 2015-09-18 WO PCT/US2015/051089 patent/WO2016044811A1/en not_active Ceased
- 2015-09-18 MX MX2017003596A patent/MX387135B/es unknown
- 2015-09-18 CN CN201580061133.2A patent/CN107002084B/zh active Active
- 2015-09-21 EP EP21166086.5A patent/EP3916084A1/en active Pending
- 2015-09-21 CA CA2961676A patent/CA2961676A1/en active Pending
- 2015-09-21 RU RU2017111300A patent/RU2763523C2/ru active
- 2015-09-21 EP EP15842405.1A patent/EP3200591B2/en active Active
- 2015-09-21 CN CN201580062281.6A patent/CN107404881B/zh active Active
- 2015-09-21 ES ES15842405T patent/ES2876235T5/es active Active
- 2015-09-21 CN CN202110690954.XA patent/CN113637640A/zh active Pending
- 2015-09-21 MX MX2017003557A patent/MX383042B/es unknown
- 2015-09-21 JP JP2017515138A patent/JP6711819B2/ja active Active
- 2015-09-21 DK DK15842405.1T patent/DK3200591T3/da active
- 2015-09-21 WO PCT/US2015/051280 patent/WO2016044853A1/en not_active Ceased
- 2015-09-21 IL IL251188A patent/IL251188B/en unknown
- 2015-09-21 KR KR1020237041649A patent/KR20230169455A/ko not_active Ceased
- 2015-09-21 BR BR112017005630-5A patent/BR112017005630B1/pt not_active IP Right Cessation
- 2015-09-21 KR KR1020177010184A patent/KR102610715B1/ko active Active
-
2016
- 2016-05-27 US US15/167,869 patent/US9914909B2/en active Active
-
2017
- 2017-03-15 IL IL251196A patent/IL251196B/en active IP Right Grant
- 2017-03-16 MX MX2021006400A patent/MX2021006400A/es unknown
- 2017-03-17 MX MX2021012720A patent/MX2021012720A/es unknown
-
2018
- 2018-03-12 US US15/918,901 patent/US10676717B2/en active Active
-
2020
- 2020-02-05 JP JP2020017583A patent/JP6986190B2/ja active Active
- 2020-05-06 US US16/867,803 patent/US20200318069A1/en active Pending
- 2020-05-28 JP JP2020093109A patent/JP7216045B2/ja active Active
- 2020-06-03 AU AU2020203651A patent/AU2020203651A1/en not_active Abandoned
-
2021
- 2021-02-02 IL IL280576A patent/IL280576B/en unknown
- 2021-10-15 JP JP2021169396A patent/JP7171871B2/ja active Active
- 2021-11-30 AU AU2021277651A patent/AU2021277651A1/en not_active Abandoned
-
2022
- 2022-05-08 IL IL292828A patent/IL292828A/en unknown
- 2022-11-02 JP JP2022176776A patent/JP2023014100A/ja active Pending
-
2023
- 2023-01-19 JP JP2023006410A patent/JP2023052506A/ja not_active Ceased
-
2024
- 2024-02-28 AU AU2024201326A patent/AU2024201326A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| Pierini et al. | Donor requirements for regulatory T cell suppression of murine graft-versus-host disease | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Bae et al. | Activation of NKT cells in an anti-PD-1–resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells | |
| Beres et al. | The role of regulatory T cells in the biology of graft versus host disease | |
| Young et al. | Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease | |
| Riley et al. | Human T regulatory cell therapy: take a billion or so and call me in the morning | |
| June | Principles of adoptive T cell cancer therapy | |
| Teschner et al. | Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis | |
| Butler et al. | Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy | |
| Ugel et al. | Immune tolerance to tumor antigens occurs in a specialized environment of the spleen | |
| Dufait et al. | Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer | |
| Reimann et al. | Human T‐Lymphoid Progenitors Generated in a Feeder‐Cell‐Free Delta‐Like‐4 Culture System Promote T‐Cell Reconstitution in NOD/SCID/γc−/− Mice | |
| MX2016013158A (es) | Productos de celulas t modificadas de genes de composicion definida. | |
| Wendel et al. | Arming immune cells for battle: a brief journey through the advancements of T and NK cell immunotherapy | |
| Kim et al. | Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease | |
| JP2016539929A5 (ru) | ||
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| JP2014526244A5 (ru) | ||
| NZ725201A (en) | Improved methods for manufacturing adoptive cell therapies | |
| CN111757745B (zh) | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 | |
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| WO2015154012A8 (en) | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations | |
| RU2011121630A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| Hromadnikova et al. | Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp 70 derived 14-Mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors on peripheral blood T cells, B cells and NKT cells |